B-MYB-p53-related relevant regulator for the progression of clear cell renal cell carcinoma

摘要

Purpose To investigate the mRNA expression ofB-MYBandMDM2together with theirp53relatedness in clear cell renal cell carcinoma (ccRCC). Methods Genes were screened for their mRNA expression from 529 patients in a publicly available ccRCC cohort (TCGA). A cohort of 101 patients with ccRCC served as validation by qRT-PCR mRNA tissue expression analysis. Results Expression: B-MYBexpression was significantly higher in high-grade tumours (p 0.05). Survival:Multivariable Cox regression of the TCGA cohort revealedB-MYBupregulation and lowMDM2expression as predictors for an impaired overall survival (OS) (HR 1.97;p= 0.0003; HR 2.94,p< 0.0001) and progression-free survival (PFS) (HR 2.86;p= 0.0005; HR 1.58,p= 0.046). In the validation cohort, the results were confirmed for OS by univariable, but not multivariable regression: highB-MYBexpression (HR = 3.05,p= 0.035) and lowMDM2expression (HR 3.81,pvalue 0.036). Conclusion In ccRCC patients with high-grade tumours and advanced stages, highB-MYBexpression is common and is associated with poorer OS and PFS. These patients show a loss of their physiologicalB-MYB-p53network correlation, suggesting an additional, alternative regulatory, oncogenic mechanism. Assuming further characterization of its signalling pathways, B-MYB could be a potential therapy target for ccRCC.